Alcohol
Volume 24, Issue 3 , Pages 169-177 , July 2001

Research with rats germane to medication for alcoholism: Consequences of noncompliance

  • Meta L Reid

      Affiliations

    • Laboratory for Psychopharmacology, 302 Carnegie Hall, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-518-276-8270; fax: +1-518-276-8268
    • ,
  • Christopher L Hubbell

      Affiliations

    • Laboratory for Psychopharmacology, 302 Carnegie Hall, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA
    • ,
  • Alison V Douglass

      Affiliations

    • Harvard Medical School, USA
    • ,
  • Kirsten L Boedeker

      Affiliations

    • University of California-Los Angeles, USA
    • ,
  • Larry D Reid

      Affiliations

    • Laboratory for Psychopharmacology, 302 Carnegie Hall, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA

Received 8 May 2000 ,Revised 3 January 2001 ,Accepted 12 February 2001.

References 

  1. Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs. 1995;49:618–649
  2. Cooper SJ. Evidence for opioid involvement in controls of drinking and water balance. In:  Rodgers RJ,  Cooper SJ editor. Endorphins, Opiates, and Behavioural Processes. Chichester: Wiley and Sons; 1988;p. 187–216
  3. Cooper SJ, Kirkham TC. Basic mechanisms of opioid effects on eating and drinking. In:  Reid LD editors. Opioids, Bulimia, and Alcohol Abuse & Alcoholism. New York: Springer-Verlag; 1990;p. 91–110
  4. Cramer CM, Gardell LR, Boedeker KL, Harris JR, Hubbell CL, Reid LD. Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol. Pharmacol Biochem Behav. 1998;60:345–356
  5. Cramer CM, Hubbell CL, Reid LD. A combination of isradipine and naltrexone blocks cocaine's enhancement of a cocaine place preference. Pharmacol Biochem Behav. 1998;60:847–853
  6. DeMet EM, Katz ML, Malekzadeh T. Effects of isradipine on alcohol craving. Soc Neurosci Abstr. 1997;23:2393
  7. Fadda F, Garau B, Colombo G, Gessa GL. Isradipine and other calcium channel antagonists attenuate ethanol consumption in ethanol-preferring rats. Alcohol Clin Exp Res. 1992;16:449–452
  8. Gardell LR, Hubbell CL, Reid LD. Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Alcohol Clin Exp Res. 1996;20:584–588
  9. Gardell LR, Reid LD, Boedeker KL, Liakos TM, Hubbell CL. Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage. Alcohol Clin Exp Res. 1997;21:1592–1598
  10. Gonzales PM, Boswell KJ, Hubbell CL, Reid LD. Isradipine blocks cocaine's ability to facilitate pressing for intracranial stimulation. Pharmacol Biochem Behav. 1997;58:1117–1122
  11. Heyser CJ, Schulteis G, Koob GF. Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol Clin Exp Res. 1997;21:784–791
  12. Hubbell CL, Reid LD. Opioids modulate rats' intake of alcoholic beverages. In:  Reid LD editors. Opioids, Bulimia, and Alcohol Abuse & Alcoholism. New York: Springer-Verlag; 1990;p. 145–174
  13. June HL, Grey C, Warren-Reese C, Durr LF, Ricks-Cord A, Johnson A, et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res. 1998;22:2174–2185
  14. Kirkham TC, Cooper SJ. Naloxone attenuation of sham feeding is modified by manipulation of sucrose concentration. Physiol Behav. 1988;44:491–494
  15. Kuzmin A, Zvartau E, Gessa GL, Martellotta MC, Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav. 1992;41:497–500
  16. Lahti RA, Collins RJ. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol. 1978;51:185–186
  17. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–887
  18. Pabello NG, Hubbell CL, Cavallaro CA, Barringer TM, Mendez JJ, Reid LD. Responding for rewarding brain stimulation: cocaine and isradipine plus naltrexone. Pharmacol Biochem Behav. 1998;61:181–192
  19. Pani L, Kuzmin A, Martellotta MC, Gessa GL, Fratta W. The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. Brain Res Bull. 1991;26:445–447
  20. Pettinati HM, Volpicelli JR, Pierce JD, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71–83
  21. Reid LD. Endogenous opioid peptides and regulation of drinking and feeding. Am J Clin Nutr. 1985;42:1099–1132
  22. Reid LD. Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Alcohol. 1996;13:5–11
  23. Reid LD, Gardell LR, Chattopadhyay S, Hubbell CL. Periodic naltrexone and propensity to take alcoholic beverage. Alcohol Clin Exp Res. 1996;20:1329–1334
  24. Reid LD, Hubbell CL. Opioids modulate rats' propensity to take alcoholic beverages. In:  Naranjo CA,  Sellers EM editor. Novel Pharmacological Interventions for Alcoholism. New York: Springer-Verlag; 1992;p. 121–134
  25. Rezvani AH, Pucilowski O, Janowsky DS. Effects of different Ca++ channel antagonists on alcohol preference in alcohol preferring rats. Alcohol Clin Exp Res. 1991;15:314
  26. Rush CR, Pazzaglia PJ. Pretreatment with isradipine, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. Alcohol Clin Exp Res. 1998;22:539–547
  27. Sinclair JD, Senter RJ. Increase preference for ethanol in rats following alcohol deprivation. Psychonomic Sci. 1967;8:11–12
  28. Stromberg MF, Volpicelli JR, O’Brien CP. Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat. Alcohol Clin Exp Res. 1998;22:2186–2191
  29. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880
  30. Volpicelli JR, O’Brien CP, Alterman AI, Hyashida M. Naltrexone and the treatment of alcohol-dependence: initial observations. In:  Reid LD editors. Opioids, Bulimia, and Alcohol Abuse & Alcoholism. New York: Springer-Verlag; 1990;p. 195–214
  31. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54:737–742
  32. Wise RA. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia. 1973;29:203–210

PII: S0741-8329(01)00153-7

doi: 10.1016/S0741-8329(01)00153-7

Alcohol
Volume 24, Issue 3 , Pages 169-177 , July 2001

Article Tools

* Image Usage & Resolution